Meta-analysis of MCP-1 promoter ?518 A/G polymorphism and SLE susceptibility

详细信息    查看全文

• 作者：Ting Liu (1)
  Jin-Xia Zhai (12) zhaijinxia@sina.com
  Han-Yong Wang (1)
  Xing-Hua Wang (1)
  Li-Wei Zou (1)
  Wen-jing Fan (1)
  Dong-Qing Ye (2)
• 关键词：Meta ; analysis – MCP ; 1 – SLE polymorphism
• 刊名：Molecular Biology Reports
• 出版年：2012
• 出版时间：August 2012
• 年：2012
• 卷：39
• 期：8
• 页码：8475-8482
• 全文大小：478.9 KB
• 参考文献：1. Harley JB, Kelly JA, Kaufman KM (2006) Unraveling the genetics of systemic lupus erythematosus. Springer Semin Immunopathol 28:119–130
  2. Davidson A, Diamond B (2001) Autoimmune diseases. N Engl J Med 345:340–350
  3. Segerer S, Nelson PJ, Schlondorff D (2000) Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 11:152–176
  4. Perez de Lema G, Maier H, Nieto E et al (2001) Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol 12:1369–1382
  5. Carr MW, Roth SJ, Luther E et al (1994) Monocyte chemoattractant protein-1 acts as a T-lymphocyte chemoattractant. Proc Nat Acad Sci USA 91:3652–3656
  6. Rovin BH, Rumancik M, Tan L et al (1994) Glomerular expression of monocyte chemoattractant protein-1 in experimental, human glomerulonephritis. Lab Invest 71:536–542
  7. Wang S, Yang N, Zhang L et al (2010) Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice. Lupus 19:1171–1180
  8. Alazawawy A, Zohary M, Ablordiny M et al (2009) Estimation of monocyte-chemoattractantprotein-1 (MCP-1) level in patients with lupus nephritis. Int J Rheum Dis 12:311–318
  9. Marks SD, Shah V, Pilkington C et al (2010) Urinary monocyte chemoattr-actant protein-1 correlates with disease activity in lupus nephritis. Pediatr Nephrol 25:2283–2288
  10. Jin O, Zhang H, Zhifeng G et al (2009) A pilot study of the therapeutic efficacy and mechanism of artesunate in the MRL/lpr murine model of systemic lupus erythematosus. Cell Mol Immunol 6:461–467
  11. Melgarejoa E, Medinaa MA, Sánchez-Jiméneza F et al (2008) Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. Int J Biochem Cell Biol 41:998–1001
  12. Rovin B, Song H, Lee A et al (2004) Urine chemokines as biomarkers of systemic lupus erythematosus activity. Clin Nephrol 16:467–473
  13. Rovin BH, Lu L, Saxena R (1999) A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 259:344–348
  14. Malafronte P, Vieira JM Jr, Pereira AC et al (2010) Monocyte chemoattractant protein-1 ?2518 A/G single nucleotide polymorphism might be associated with renal disease and thrombocytopenia of SLE. J Rheumatol 37:776–782
  15. Piotrowski P, Lianeri M, Gasik R et al (2010) Monocyte chemoattractant protein-1 ?2518 A/G single nucleotide polymorphism might be associated with renal disease and thrombocytopenia of SLE. J Biomed Biotechnol 2010:130265
  16. Wang Y, Deng D, Mao C et al (2007) Study on the association between MCP-1-2518 promoter polymorphism and systemic lupus erythematosus in Chinese Him in Yunnan Provinc. Int J Immunol 30(5–8):12
  17. Lima G, Soto-Vega E, Atisha-Fregoso Y et al (2007) MCP-1, RANTES, SDF-1 polymorphisms in Mexican patients with systemic lupus erythematosus. Hum Immunol 68:980–985
  18. Brown KS, Nackos E, Morthala S, Jensen LE, Whitehead AS, Von Feldt JM (2007) Monocyte chemoattractant protein-1: plasma concentrations and A(-2518)G promoter polymorphism of its gene in systemic lupus erythematosus. J Rheumatol 34:740–746
  19. Sanchez E, Sabio JM, Callejas JL, de Ramon E, Garcia-Portales R, Garcia-Hernandez FJ et al (2006) Association study of genetic variants of pro-inflammatory chemokine and cytokine genes in systemic lupus erythematosus. BMC Med Genet 7:48
  20. Ye DQ, Hu YS, Li XP, Yang SG, Hao JH, Huang F et al (2005) The correlation between monocyte chemoattractant protein-1, the arthritis of systemic lupus erythematosus among Chinese. Arch Dermatol Res 296:366–371
  21. Liao CH, Yao TC, Chung HT, See LC, Kuo ML, Huang JL (2004) Polymorphisms in the promoter region of RANTES, the regulatory region of monocyte chemoattractant protein-1 among Chinese children with systemic lupus erythematosus. J Rheumatol 31:2062–2067
  22. Tucci M, Barnes EV, Sobel ES, Croker BP, Segal MS, Reeves WH et al (2004) Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthr Rheum 50:1842–1849
  23. Nakashima H, Akahoshi M, Shimizu S, Inoue Y, Miyake K, Ninomiya I et al (2004) Absence of association between the MCP-1 gene polymorphism and histological phenotype of lupus nephritis. Lupus 13:165–167
  24. Kim HL, Lee DS, Yang SH, Lim CS, Chung JH, Kim S et al (2002) The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE. Am J Kidney Dis 40:1146–1152
  25. Hwang SY, Cho ML, Park B, Kim JY, Kim YH, Min DJ et al (2002) Allelic frequency of the MCP-1 promoter -2518 polymorphism in the Korean population, in Korean patients with rheumatoid arthritis, systemic lupus erythematosus, adult-onset Still’s disease. Eur J Immunogenet 29:413–416
  26. Aguilar F, Gonzalez-Escribano MF, Sanchez-Roman J, Nunez-Roldan A (2001) MCP-1 promoter polymorphism in Spanish patients with systemic lupus erythematosus. Tissue Antigens 58:335–338
  27. Hoshi D, Okamoto H, Kaneko H, Ichikawa N, Terai C, Yamanaka H, Kamatani N (2008) Association of a polymorphism in the monocyte chemoattractant protein-1/CCL2 gene and lupus nephritis in systemic lupus erythematosus patients. Clin Exp Rheumatol 26:972–973
  28. Egger M, Smith GD, Phillips AN (1997) Meta-analysis: principles and procedures. BMJ 315:1533–1537
  29. Lee YH, Woo J-H, Choi SJ, Ji JD, Song GG (2010) Functional monocyte chemoattractant protein-1 promoter -2518 polymorphism and systemic lupus erythematosus: a meta-analysis. Mol Biol Rep 37:3421–3426
  30. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129
  31. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558
  32. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Nat Cancer Inst 22:719–748
  33. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
  34. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315:629–634
  35. Love LA (1994) New environmental agents associated with lupus like disorders. Lupus 3:467–471
  36. Tse KP, Tsang NM, Chen KD (2007) MCP-1 promoter polymorphism at 2518 is associated with metastasis of nasopharyngeal carcinoma after treatment. Clin Cancer Res 13:6320
  37. Nahon P, Sutton A, Rufat P et al (2007) Lack of association of some chemokine polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients of alcoholic cirrhosis: a prospective study. Eur J Gastroenterol Hepatol 19:425
  38. Nahon P, Sutton A, Rufat P et al (2008) Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. World J Gastroenterol 14:713
  39. Ghilardi G, Biondi ML, La TA et al (2005) Breast cancer progression and host polymorphism in the chemokine system: role of the macrophage chemoattractant protein-1(MCP-1)-2518 G allele. Clin Chem 51:452
  40. Tucci M, Chang MK, Boullier A et al (2006) Deregulated expression of monocyte chemoattracant protein-1(MCP-1) in arterial hypertension: role in endothelial inflammation and atheromasia. Hypertension 24:1307–1318
  41. Schober A, Zernecke A (2007) Chemokines in vascular remodeling. Thromb Haemost 97:730–737
  42. Barbado J, Vega L, Gonzalez-Gallego R et al (2010) MCP-1 in urine as biomaker of renal lupus in absence of cytokines, interferon-γ and growth factors. Reumatol Clin 6:296–298
  43. Fenoglio C, Galimberti D, Lovati C et al (2008) MCP-1 in Alzheimer’s disease patients: a-2518G polymorphism and Tunisian patients. Clin Chim Acta 390:122–125
• 作者单位：1. Department of Occupational and Environmental Health, School of Public Health, Anhui Medical University, Meishan Road, Hefei, 230032 Anhui, China2. Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 69 Meishan Road, Hefei, 230032 Anhui, China
• ISSN：1573-4978

文摘

The aim of this meta-analysis was to summarize results on the association of monocyte chemoattractant protein-1(MCP-1) promoter ?2518 A/G polymorphism with systemic lupus erythematosus (SLE) susceptibility. We searches all the publications about the association between MCP-1 promoter ?2518 A/G polymorphism and SLE from Pubmed, Elsevier Science Direct, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure. The meta-analysis was performed for genotypes AA verse GG, AA+AG verse GG, AA verse AG+GG, and A allele verse G allele in a fixed/random effect model. A total of 14 studies (2,333 cases and 2,391 controls) were included in the meta-analysis. When all groups were pooled, we had not observed significant association between A allele and G allele (OR = 0.94, 95 %CI = 0.79–1.12, P = 0.50). When analysis were restricted to more ethnically homogeneous populations, the similar results were found in European population and Asian population (OR = 1.05, 95 %CI = 0.75–1.46, P = 0.80; OR = 1.00, 95 %CI = 0.86–1.17, P = 0.99). However, we had not detected a significant association between MCP-1 promoter ?2518 A/G polymorphism and SLE when examining the genotypes AA verse GG, AA+AG verse GG, AA verse AG+GG. The meta-analysis did not demonstrate the association between MCP-1 promoter ?2518 A/G polymorphism and SLE.